Having had over a decade to mature, the RNAi drugs industry has more therapeutic candidates in clinical development than ever, testing in humans agents that incorporate a variety of designs, modifications, and delivery strategies.
Below is a list of the key RNAi-based therapies currently under active development, broken down by their developer.
...
Sylentis
SYL040012 — This drug is an unmodified 21-mer designed to silence adrenergic receptor beta-2 as a way to treat the ocular hypertension and elevated intraocular pressure associated with open-angle glaucoma.
Administered as eye drops, the drug has been tested in three clinical trials thus far, including a recently completed phase II trial. A phase IIb study is planned for this year.
SYL1001 — Like Sylentis' other drug, SYL1001 is an unmodified siRNA that is delivered topically to the eye. It targets transient receptor potential cation channel subfamily V member 1, which plays a role in pain sensitivity, for ocular pain.
The agent is currently under phase I/II testing for dry eye syndrome.
...